ArticleGynecologic oncology reports2023

Activity of pembrolizumab and lenvatinib in mismatch repair deficient (dMMR) endometrial cancer patients who have failed pembrolizumab monotherapy: A case series.

Peter G Rose et al.PubMed ↗Full text ↗Publisher ↗

No numbers read from the abstract.